Using S1R-selective [18F] fluspidine PET, we demonstrate for the first time in vivo a high and selective S1R receptor occupancy (approx. 90%) by pridopidine in HVs and patients with HD, at a dose of 90 mg (plasma exposure correlates to 45 mg bid at steady state). This evidence concerns the gene TMBIM4 and Huntington disease.